{"entity":{"id":"nct07283835","kind":"trial","name":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","aka":[],"tldr":"A phase 2 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by Lepu Biopharma Co., Ltd., now recruiting.","summary":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin is a phase 2 interventional study registered as NCT07283835 by Lepu Biopharma Co., Ltd., with 16 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Cretostimogene Grenadenorepvec.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07283835","url":"https://clinicaltrials.gov/study/NCT07283835"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["cretostimogene"],"companies":["lepu-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07283835","phase":"2","setting":"A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Cretostimogene Grenadenorepvec in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer","sponsor":"Lepu Biopharma Co., Ltd.","enrolled":16,"outcomes":[]},"route":"/trials/nct07283835/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/"}],"company":[{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/"}]}}